Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Barclays PLC Major Shareholding Notification 2021

Feb 2, 2021

5250_rns_2021-02-02_2dbc4367-3f90-4875-ba36-29acbf5261b2.html

Major Shareholding Notification

Open in viewer

Opens in your device viewer

National Storage Mechanism | Additional information

Form 8.3 - WILLIS TOWERS WATSON PLC

Ap19

FORM 8.3

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

1. KEY INFORMATION

Name of person dealing (Note 1) Barclays PLC.
Company dealt in WILLIS TOWERS WATSON PLC
Class of relevant security to which the ORD
dealings being disclosed relate (Note 2)
Date of dealing 01 February 2021

2. INTERESTS AND SHORT POSITIONS

(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

Class of relevant security: ORD
Long Short
Number (%) Number (%)
(1) Relevant securities
2,315,255 1.80% 605,642 0.47%
(2) Derivatives (other than options):
273,127 0.21% 455,399 0.35%
(3) Options and agreements to
purchase/sell: 6,000 0.00% 6,000 0.00%
TOTAL:
2,594,382 2.01% 1,067,041 0.83%

(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

Class of relevant security: Long Short
Number (%) Number (%)
(1) Relevant securities
(2) Derivatives (other than options)
(3) Options and agreements to purchase/sell
Total

Ap20

1. DEALINGS (Note 4)

(a) Purchases and sales

Purchase/sale Number of relevant securities Price per unit
Purchase 1 207.5300 USD
Purchase 3 207.4166 USD
Purchase 3 207.3316 USD
Purchase 94 207.4200 USD
Purchase 100 207.7900 USD
Purchase 166 205.1902 USD
Purchase 187 206.5725 USD
Purchase 200 208.2800 USD
Purchase 486 204.9068 USD
Purchase 501 207.9092 USD
Purchase 604 207.8846 USD
Purchase 610 208.0027 USD
Purchase 872 208.1790 USD
Purchase 1,008 207.9487 USD
Purchase 1,022 207.6778 USD
Purchase 1,095 206.8811 USD
Purchase 1,200 207.4193 USD
Purchase 1,447 207.5149 USD
Purchase 1,600 207.3192 USD
Purchase 2,007 207.7350 USD
Purchase 2,541 207.4010 USD
Purchase 2,930 207.6738 USD
Purchase 2,974 207.5626 USD
Purchase 3,865 207.7965 USD
Purchase 4,585 207.5435 USD
Purchase 4,714 207.5666 USD
Purchase 7,703 207.4500 USD
Purchase 8,793 207.4357 USD
Purchase 10,000 207.8079 USD
Purchase 16,161 207.1892 USD
Purchase 18,525 207.6271 USD
Purchase 19,498 207.1930 USD
Purchase 53,182 207.0048 USD
Purchase 59,800 207.6650 USD
Purchase 76,734 207.4992 USD
Sale 5 206.4900 USD
Sale 40 205.1000 USD
Sale 80 207.9025 USD
Sale 97 204.0400 USD
Sale 100 209.4700 USD
Sale 100 207.9200 USD
Sale 100 207.9400 USD
Sale 120 207.7250 USD
Sale 120 207.6666 USD
Sale 176 207.2000 USD
Sale 200 207.7900 USD
Sale 203 204.8688 USD
Sale 243 204.9068 USD
Sale 376 208.5071 USD
Sale 621 207.5834 USD
Sale 805 207.2708 USD
Sale 1,003 206.8275 USD
Sale 1,030 206.8533 USD
Sale 1,200 207.4193 USD
Sale 1,400 206.4382 USD
Sale 1,500 206.5160 USD
Sale 1,623 206.4733 USD
Sale 1,807 206.9958 USD
Sale 1,826 207.8013 USD
Sale 1,840 206.7901 USD
Sale 1,879 203.9743 USD
Sale 1,955 207.4500 USD
Sale 2,570 207.3616 USD
Sale 3,174 207.4590 USD
Sale 4,268 207.7422 USD
Sale 4,585 207.5435 USD
Sale 4,815 207.2371 USD
Sale 5,745 207.2090 USD
Sale 5,773 207.4499 USD
Sale 6,954 207.4398 USD
Sale 9,223 207.0852 USD
Sale 10,870 207.7311 USD
Sale 11,547 207.3135 USD
Sale 12,113 207.1402 USD
Sale 15,093 206.9628 USD
Sale 28,232 207.5258 USD
Sale 59,800 207.6650 USD
Sale 100,000 207.5250 USD

(b) Derivatives transactions (other than options transactions)

Product name,

e.g. CFD
Nature of transaction

(Note 6)
Number of relevant securities

(Note 7)
Price per unit

(Note 5)

(c) Options transactions in respect of existing relevant securities

(i) Writing, selling, purchasing or varying

Product name,

e.g. call option
Writing, selling, purchasing, varying etc. Number of securities to which the option relates (Note 7) Exercise price Type, e.g. American, European etc. Expiry date Option money paid/received per unit (Note 5)

(ii) Exercising

Product name,

e.g. call option
Number of securities Exercise price per unit (Note 5)

(d) Other dealings (including transactions in respect of new securities) (Note 4)

Nature of transaction

(Note 8)
Details Price per unit

(if applicable) (Note 5)

Ap21

2. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

None

Is a Supplemental Form 8 (Open Positions) attached? YES
Date of disclosure: 2 Feb 2021
Contact name: Large Holdings Regulatory Operations
Telephone number: 020 3134 7213
If a connected EFM, name of offeree/offeror with which connected
If a connected EFM, state nature of connection

Ap23

SUPPLEMENTAL FORM 8

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.1 AND RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DETAILS OF OPEN POSITIONS

(This form should be attached to Form 8.1(a) & (b)(i), Form 8.1(b)(ii) or Form 8.3, as appropriate)

OPEN POSITIONS (Note 1)

Product name Written or Number of Exercise Type Expiry
purchased relevant securities price date
to which the option
or derivative
relates
Call Options Purchased 6,000 220.0000 American Jul 16, 2021
Put Options Purchased -6,000 200.0000 American Jul 16, 2021

Notes

1. Where there are open option positions or open derivative positions (except for CFDs), full details should be given. Full details of any existing agreements to purchase or to sell must also be given on this form.

2. For all prices and other monetary amounts, the currency must be stated.

For full details of disclosure requirements, see Rule 8 of the Rules. If in doubt, consult the Panel.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210202005600/en/

BARCLAYS PLC